Licensed in Japan as a diagnostic agent
Japan's medicines regulator (PMDA) lists a pralmorelin hydrochloride product, GHRP Kaken 100 Injection from Kaken Pharmaceutical, with one authorised indication: the diagnosis of growth hormone secretion deficiency. The package insert shows marketing began in February 2005. It is authorised as a test substance, not as a treatment.
- Study type
- Regulatory-clinical source
- Population
- Not applicable (regulatory record)
- Source
- 1 Pharmaceuticals and Medical Devices Agency (PMDA) et al., 2025
Limitation: A Japanese-language regulator record.
Limitations in full
A Japanese-language regulator record. It shows the authorised use and marketing history, not clinical performance. The approval number is 21600AMZ00573; the page read did not state the approval date. Not a UK or EU licence.